XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Third Party Agreements - Additional Information (Details) - USD ($)
$ in Thousands
6 Months Ended 9 Months Ended 12 Months Ended
Jul. 31, 2019
Jul. 29, 2016
Jun. 30, 2020
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2018
Dec. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Incurred costs related       $ 800      
Licence agreement additional revenue recognised       5,000      
Licence agreement cumulative revenue recognised         $ 35,300    
Regeneron Pharmaceuticals, Inc.              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Exercise Fee Paid       20,000      
Contingent Consideration fees   $ 20,000          
Option exercise fee       20,000      
Contract Assets       100      
Agreement transaction price   55,000          
Licence agreement additional revenue recognised       25,000      
Research funding fee   30,000          
Non refundable upfront payment received       25,000      
Additional payment for research funding received   30,000   $ 20,000   $ 5,000 $ 5,000
License agreement termination description       twelve (12) years      
Upfront payment   $ 25,000     25,000    
Licence agreement cumulative revenue recognised     $ 10,000        
Increase in estimated transaction price $ 35,000            
Contract liability       $ 0 $ 10,100    
Regeneron Pharmaceuticals, Inc. | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Licence agreement additional amount payable of option exercise fees       80,000      
Increase in estimated transaction price       45,000      
Regeneron Pharmaceuticals, Inc. | Minimum [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Increase in estimated transaction price       $ 10,000